First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP‐ribose) Polymerase‐1 Inhibitor, JPI-289, in Healthy Volunteers

BACKGROUND: Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor has therapeutic potential for acute ischemic stroke by suppressing microglial activation and facilitating neuroprotection. In this first-in-human study, we investigate the safety, tolerability and pharmacokinetics (PK) of JPI-289 in healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Sungpil, Kim, Yo Han, Choi, Hee Youn, Soh, Dong-Jun, Kim, Jeongmin, Nam, Joonwoo, Kim, Jong-Woo, Bae, Kyun-Seop, Lim, Hyeong-Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415440/
https://www.ncbi.nlm.nih.gov/pubmed/32801651
http://dx.doi.org/10.2147/DDDT.S235802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415440/
https://www.ncbi.nlm.nih.gov/pubmed/32801651
http://dx.doi.org/10.2147/DDDT.S235802

Ejemplares similares